GLP-1 Oral Solid Composition Using High-SNAC Absorption Enhancement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human GLP-1 and its analogues have low oral bioavailability, leading to challenges in achieving effective plasma exposure through oral administration due to rapid degradation in the gastrointestinal system.
Innovation Solution
A pharmaceutical composition comprising a high content of an absorption enhancer, such as SNAC, with minimal excipients, enabling accelerated absorption of GLP-1 agonists within 15-30 minutes after oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of GLP-1 agonist is performed with conventional formulations, then the formulation is simple to manufacture, but the plasma exposure and bioavailability remain very low due to rapid degradation
Solution Approach 1:
The patent introduces SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) as an intermediary substance that mediates between the GLP-1 agonist and the gastrointestinal environment. SNAC forms a complex with the peptide, protecting it from degradation and enhancing its absorption across the intestinal wall, thereby significantly improving plasma exposure without requiring complex formulation strategies
Solution Approach 2:
The patent optimizes the concentration parameter of SNAC in the formulation, using a high concentration (at least 90% of excipients) to maximize the absorption enhancement effect. This parameter change transforms the formulation from a conventional low-complexity design to one that relies on precise control of excipient concentration to achieve reliable plasma exposure
2Reliability
If absorption enhancers are added to improve bioavailability, then plasma exposure increases, but the composition requires precise control of excipient ratios
Solution Approach 1:
The patent establishes a specific parameter range for SNAC concentration (at least 90% of excipients) that optimizes the balance between absorption enhancement and manufacturing feasibility. This precise parameter control ensures reliable bioavailability improvement while providing clear manufacturing specifications
Solution Approach 2:
The patent creates a composite formulation where SNAC and GLP-1 agonist work synergistically. The composite nature of this combination requires precise control of the excipient ratio to maintain the optimal synergistic effect, thereby improving bioavailability while necessitating careful manufacturing precision
3Speed
If minimal excipients are used to accelerate absorption, then the absorption speed increases within 15-30 minutes, but the formulation requires very high content of delivery agent
Solution Approach 1:
The patent extracts and eliminates unnecessary excipients from the formulation, retaining only SNAC as the essential delivery agent. This extraction of superfluous components accelerates absorption by removing potential barriers to rapid peptide uptake, achieving 15-30 minute absorption times
Solution Approach 2:
The patent dramatically changes the concentration parameter of the delivery agent SNAC, increasing it to at least 90% of excipients. This extreme parameter value ensures that the formulation is dominated by the absorption-enhancing component, thereby maximizing absorption speed while requiring very high delivery agent content
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves increased plasma exposure of GLP-1 agonists, with the absorption enhancer constituting at least 90% of the composition, facilitating fast and efficient uptake.
Implementation Method 1
The provided compositions display an accelerated absorption, enabling fast and efficient uptake of the active pharmaceutical ingredient
Data Source
AI summary
The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.